리소좀 질환 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 치료법별, 투여 경로별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Lysosomal Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Therapy, By Route Of Administration, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 리소좀 질환 치료 시장은 2024년에 81억 달러로 평가되었으며, 2030년까지 CAGR 7.10%로 성장하여 122억 2,000만 달러에 달할 것으로 예측됩니다.

세계 리소좀 질환 치료 시장은 효소 결핍으로 인해 세포 내 리소좀에 기질이 축적되는 희귀 유전성 질환인 리소좀 축적증(LSD)에 대한 치료적 개입을 포함합니다. 시장 성장 촉진요인으로는 인지도 향상, 진단기술의 발전으로 인한 조기 환자 발견, 효소대체요법, 기질감소요법, 유전자 치료의 바이오테크놀러지의 발전 등을 들 수 있습니다. 희귀질환 치료제 지정 및 특혜를 바탕으로 한 연구개발 환경의 확대는 이 전문 치료 분야에 대한 투자를 더욱 촉진하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	81억 달러
시장 규모 : 2030년	122억 2,000만 달러
CAGR : 2025-2030년	7.1%
가장 빠르게 성장하는 부문	효소보충요법
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 유형별(뮤코다당증, 폼페병, 파브리병, 고셔병, 기타)
  • 치료법별(기질감소요법, 줄기세포 치료, 효소보충요법, 기타)
  • 투여 경로별(경구, 비경구, 기타)
  • 최종사용자별(병원, 전문 클리닉, 재택의료, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 리소좀 질환 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 리소좀 질환 치료 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Novartis AG
• Johnson & Johnson Services, Inc.
• Amicus Therapeutics, Inc.
• Merck & Co., Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Lysosomal Disease Treatment Market, valued at USD 8.10 Billion in 2024, is projected to experience a CAGR of 7.10% to reach USD 12.22 Billion by 2030. The Global Lysosomal Disease Treatment Market encompasses therapeutic interventions for lysosomal storage disorders (LSDs), rare genetic conditions where enzyme deficiencies cause substrate accumulation within cellular lysosomes. Market growth drivers include increasing awareness, improved diagnostics leading to earlier patient identification, and biotechnology advancements in enzyme replacement, substrate reduction, and gene therapies. An expanding research and development landscape, bolstered by orphan drug designations and incentives, further stimulates investment in this specialized therapeutic area.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 8.10 Billion
Market Size 2030	USD 12.22 Billion
CAGR 2025-2030	7.1%
Fastest Growing Segment	Enzyme Replacement Therapy
Largest Market	North America

Key Market Drivers

The robust pipeline and continuous development of novel therapeutic modalities significantly propel the global lysosomal disease treatment market. Innovations in enzyme replacement therapies, gene therapies, and substrate reduction therapies offer improved efficacy and address previously untreatable manifestations of these complex disorders. For example, the U. S. Food and Drug Administration approved Pombiliti(TM) and Opfolda(TM), a two-component therapy for adults with late-onset Pompe disease, representing a significant advancement in treatment options. According to Amicus Therapeutics, in September 2023, this approval marked the first and only two-component therapy for eligible adults living with the condition. Such advancements expand the treatable patient population and enhance therapeutic outcomes, fostering market growth through increased product adoption and sustained patient engagement.

Key Market Challenges

The high cost associated with specialized treatments for lysosomal diseases presents a significant impediment to market growth. These substantial expenses strain healthcare budgets globally, leading to restrictive reimbursement policies and protracted negotiation processes with payers. Such financial barriers directly limit patient access to approved therapies, even when innovative interventions are available. This directly decelerates market penetration and revenue generation for lysosomal disease treatments.

Key Market Trends

Personalized medicine integration in therapy development signifies a shift towards tailoring treatments to individual patient profiles, utilizing genetic and molecular biomarker information to optimize therapeutic outcomes. This approach moves beyond conventional generalized treatments, focusing on patient-specific needs for enhanced efficacy and reduced adverse effects, particularly crucial in complex rare diseases like lysosomal storage disorders. As per the Personalized Medicine Coalition, a nonprofit based in the US, the FDA sanctioned 16 innovative personalized treatments for rare disease sufferers in 2023, representing a substantial increase from six approvals in 2022.

Key Market Players

• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Novartis AG
• Johnson & Johnson Services, Inc.
• Amicus Therapeutics, Inc.
• Merck & Co., Inc.

Report Scope:

In this report, the Global Lysosomal Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lysosomal Disease Treatment Market, By Disease Type:

• Mucopolysaccharidosis
• Pompes Syndrome
• Fabry Diseases
• Gaucher's Disease
• Other

Lysosomal Disease Treatment Market, By Therapy:

• Substrate Reduction Therapy
• Stem Cell Therapy
• Enzyme Replacement Therapy
• Other

Lysosomal Disease Treatment Market, By Route Of Administration:

• Oral
• Parenteral
• Other

Lysosomal Disease Treatment Market, By End User:

• Hospitals
• Specialty Clinics
• Homecare
• Other

Lysosomal Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lysosomal Disease Treatment Market.

Available Customizations:

Global Lysosomal Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lysosomal Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Mucopolysaccharidosis, Pompes Syndrome, Fabry Diseases, Gaucher's Disease, Other)
  • 5.2.2. By Therapy (Substrate Reduction Therapy, Stem Cell Therapy, Enzyme Replacement Therapy, Other)
  • 5.2.3. By Route Of Administration (Oral, Parenteral, Other)
  • 5.2.4. By End User (Hospitals, Specialty Clinics, Homecare, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Lysosomal Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy
  • 6.2.3. By Route Of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lysosomal Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Route Of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Lysosomal Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Route Of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Lysosomal Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Route Of Administration
      • 6.3.3.2.4. By End User

7. Europe Lysosomal Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy
  • 7.2.3. By Route Of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lysosomal Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Route Of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Lysosomal Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Route Of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Lysosomal Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Route Of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Lysosomal Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Route Of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Lysosomal Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Route Of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Lysosomal Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy
  • 8.2.3. By Route Of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lysosomal Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Route Of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Lysosomal Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Route Of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Lysosomal Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Route Of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Lysosomal Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Route Of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Lysosomal Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Route Of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Lysosomal Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy
  • 9.2.3. By Route Of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lysosomal Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Route Of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Lysosomal Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Route Of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Lysosomal Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Route Of Administration
      • 9.3.3.2.4. By End User

10. South America Lysosomal Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy
  • 10.2.3. By Route Of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lysosomal Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Route Of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Lysosomal Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Route Of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Lysosomal Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Route Of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lysosomal Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Takeda Pharmaceutical Company Limited
• 15.3. Sanofi SA
• 15.4. Novartis AG
• 15.5. Johnson & Johnson Services, Inc.
• 15.6. Amicus Therapeutics, Inc.
• 15.7. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료